Droperidol Sintetica

What Is Droperidol Sintetica and What Is It Used For?

Droperidol is a potent butyrophenone derivative that has been used in clinical medicine since the 1960s. It was originally developed as a component of neuroleptanalgesia – a technique combining a neuroleptic agent with an opioid analgesic for surgical anaesthesia. While its role in anaesthesia has evolved over the decades, droperidol remains a valuable medication in modern perioperative care and emergency medicine.

The primary indication for Droperidol Sintetica is the prevention and treatment of postoperative nausea and vomiting (PONV). PONV is one of the most common complications following general anaesthesia, affecting approximately 30% of all surgical patients and up to 80% of high-risk patients. Multiple international guidelines, including those from the Society for Ambulatory Anesthesia (SAMBA) and the European Society of Anaesthesiology (ESA), recommend droperidol as a first-line antiemetic for PONV prevention. At low doses (0.625–1.25 mg IV), droperidol is highly effective, with a number needed to treat (NNT) of approximately 5 for PONV prevention.

The second major indication is management of acute agitation and aggression in emergency and psychiatric settings. Droperidol provides rapid tranquillisation with an onset within minutes, making it particularly useful when rapid behavioural control is necessary for patient and staff safety. Several emergency medicine guidelines, including those from the National Institute for Health and Care Excellence (NICE) and the American Association for Emergency Psychiatry (AAEP), include droperidol among their recommended agents for acute agitation.

Mechanism of Action

Droperidol exerts its pharmacological effects primarily through antagonism of dopamine D2 receptors in the central nervous system. In the chemoreceptor trigger zone (CTZ) of the medulla oblongata, dopamine D2 receptor blockade produces the antiemetic effect. The CTZ lies outside the blood-brain barrier in the area postrema, making it sensitive to emetogenic stimuli from both the blood and cerebrospinal fluid. By blocking dopamine signalling in this region, droperidol effectively suppresses the vomiting reflex.

Beyond D2 receptor antagonism, droperidol also demonstrates activity at several other receptor systems. It blocks alpha-1 adrenergic receptors, which can cause mild peripheral vasodilation and a modest reduction in blood pressure. It also has affinity for serotonin 5-HT2 receptors and histamine H1 receptors, both of which may contribute to its antiemetic and sedative properties. The gamma-aminobutyric acid (GABA) receptor system may also play a role in its anxiolytic effects.

The pharmacokinetic profile of droperidol is characterised by rapid onset and relatively short duration. When administered intravenously, clinical effects begin within 3 to 10 minutes. Intramuscular administration provides onset within 15 to 20 minutes. The sedative and antiemetic effects typically last 2 to 4 hours, though alterations in consciousness and alertness may persist for up to 12 hours. Droperidol is extensively metabolised in the liver, primarily through N-dealkylation and oxidation, and has a terminal elimination half-life of approximately 2 to 3 hours.

What Should You Know Before Taking Droperidol Sintetica?

Before administering Droperidol Sintetica, healthcare professionals must conduct a thorough assessment of the patient's medical history, current medications, and cardiac risk factors. This drug carries a boxed warning in several countries regarding the risk of QT prolongation and torsades de pointes, making pre-treatment evaluation critical for patient safety.

Contraindications

Droperidol Sintetica must not be used in the following situations:

• Known QT interval prolongation – Including congenital long QT syndrome or acquired QT prolongation from any cause. The baseline corrected QT interval (QTc) should be less than 440 ms in men and less than 450 ms in women before droperidol is administered.
• Hypokalemia or hypomagnesemia – Electrolyte imbalances significantly increase the risk of QT prolongation and cardiac arrhythmias. Electrolytes should be corrected before administration.
• Pheochromocytoma – Droperidol may provoke a hypertensive crisis in patients with catecholamine-secreting tumours.
• Parkinson's disease – Dopamine D2 receptor blockade will worsen parkinsonian symptoms and may precipitate akinetic crisis.
• Known hypersensitivity to droperidol, other butyrophenones, or any of the excipients.
• Comatose states – Including severe CNS depression from any cause.
• Concurrent use with other QT-prolonging drugs where the combination is deemed to carry unacceptable cardiac risk.

Warnings and Precautions

Additional warnings and precautions include:

• Cardiovascular disease – Use with caution in patients with heart failure, bradycardia, cardiac hypertrophy, or a history of cardiac arrhythmias. Alpha-adrenergic blockade may cause hypotension, particularly in hypovolemic patients.
• Elderly patients – Increased sensitivity to the cardiovascular and CNS effects of droperidol. Lower doses should be used, and the duration of monitoring should be extended.
• Hepatic impairment – As droperidol is extensively metabolised in the liver, dose reduction may be necessary in patients with significant hepatic dysfunction.
• Renal impairment – Approximately 75% of the drug is excreted via the kidneys. Dose adjustment may be needed in severe renal impairment.
• Neuroleptic malignant syndrome (NMS) – A rare but potentially fatal reaction characterised by hyperthermia, muscle rigidity, altered consciousness, and autonomic instability. Droperidol should be discontinued immediately if NMS is suspected.
• Extrapyramidal symptoms (EPS) – Dystonia, akathisia, and other movement disorders may occur, particularly with higher doses or prolonged use.
• Epilepsy – Droperidol may lower the seizure threshold. Use with caution in patients with a history of seizures.
• CNS depression – Droperidol potentiates the effects of other CNS depressants. Patients should not drive or operate machinery for at least 24 hours after administration.

Pregnancy and Breastfeeding

Droperidol is classified as a Category C drug in pregnancy. Animal reproduction studies have demonstrated adverse effects on the foetus, but there are insufficient well-controlled studies in pregnant women. Droperidol crosses the placental barrier and may cause neonatal respiratory depression and extrapyramidal symptoms in the newborn if administered during the third trimester or during labour.

The use of droperidol during pregnancy should be reserved for situations where the potential benefit clearly outweighs the potential risk to the foetus. If droperidol is administered near term or during labour, the neonate should be carefully monitored for signs of CNS depression, respiratory depression, and extrapyramidal symptoms.

It is not known whether droperidol is excreted in human breast milk. Given its pharmacological properties and the potential for serious adverse effects in nursing infants, breastfeeding should be discontinued during treatment and for at least 24 hours after the last dose.

How Does Droperidol Sintetica Interact with Other Drugs?

Drug interactions with droperidol are clinically significant and can be life-threatening. Healthcare professionals must review all concomitant medications before administering this drug. The interactions can be broadly categorised into pharmacodynamic interactions (affecting drug action) and pharmacokinetic interactions (affecting drug metabolism).

Major Interactions

Minor Interactions

In addition to the interactions listed above, clinicians should be aware that CYP3A4 inhibitors (such as ketoconazole, itraconazole, and ritonavir) may increase droperidol plasma levels by reducing hepatic metabolism. Conversely, strong CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin) may decrease droperidol efficacy by accelerating its metabolism.

Patients taking diuretics (particularly thiazides and loop diuretics) should have their electrolyte levels checked before droperidol administration, as diuretic-induced hypokalemia or hypomagnesemia can potentiate the QT-prolonging effects of droperidol.

What Is the Correct Dosage of Droperidol Sintetica?

Droperidol Sintetica is formulated as a 0.5 mg/ml solution for injection, allowing precise dose titration. It is administered exclusively by trained healthcare professionals in supervised clinical settings. The dosage varies depending on the indication, patient age, body weight, and individual risk factors. A baseline 12-lead ECG is recommended before administration.

Adults

Children

The safety and efficacy of Droperidol Sintetica in children under 2 years of age have not been established. For children aged 2 years and older, droperidol may be used for PONV prevention at a dose of 10–50 micrograms/kg (maximum 1.25 mg) by slow intravenous injection, administered near the end of surgery. The use of droperidol for acute agitation in children requires specialist paediatric assessment and is generally reserved for adolescents over 12 years of age.

Weight-based dosing should always be used in paediatric patients, and the dose should be carefully calculated and verified before administration. Continuous monitoring of vital signs, including heart rate and rhythm, is essential throughout the treatment period.

Elderly

Elderly patients (over 65 years) show increased sensitivity to the pharmacological effects of droperidol, particularly the cardiovascular effects (hypotension, QT prolongation) and CNS effects (excessive sedation, confusion). The following adjustments are recommended:

• Start with the lowest recommended dose (0.625 mg for PONV)
• Allow adequate time to assess response before considering repeat dosing
• Extend cardiac monitoring to at least 3 hours after the last dose
• Ensure adequate hydration to minimise hypotensive effects
• Monitor closely for extrapyramidal symptoms, which are more common in this age group

Missed Dose

Since Droperidol Sintetica is administered by healthcare professionals in a clinical setting, the concept of a missed dose does not typically apply. For scheduled PONV prophylaxis, if the intended dose was not administered before the end of surgery, the clinician should assess whether post-operative administration is still warranted based on the patient's individual risk factors and clinical status.

Overdose

Management of droperidol overdose is primarily supportive and symptomatic:

• Airway management – Secure the airway and provide mechanical ventilation if respiratory depression occurs
• Cardiovascular support – Intravenous fluids for hypotension; vasopressors (norepinephrine or phenylephrine) if needed. Avoid epinephrine as it may worsen hypotension due to beta-2 stimulation in the presence of alpha blockade
• Cardiac monitoring – Continuous ECG monitoring; treat torsades de pointes with intravenous magnesium sulphate and overdrive pacing if necessary
• Extrapyramidal symptoms – Treat with anticholinergic agents such as benztropine (1–2 mg IV) or procyclidine
• Seizures – Treat with benzodiazepines (diazepam or lorazepam)

What Are the Side Effects of Droperidol Sintetica?

Like all medicines, Droperidol Sintetica can cause side effects, although not everybody gets them. The frequency and severity of side effects are generally dose-dependent. Lower doses used for PONV prophylaxis (0.625–1.25 mg) are associated with fewer and milder side effects compared to higher doses used for acute agitation.

The following side effect classification uses the internationally standardised frequency categories defined by the Council for International Organizations of Medical Sciences (CIOMS):

It is important to note that many of the more serious side effects listed above are associated with higher doses or the presence of predisposing risk factors. At the low doses used for PONV prevention (0.625–1.25 mg), the incidence of serious cardiac events is extremely low. A comprehensive meta-analysis published in Anesthesiology (2009) reviewed over 6,000 patients receiving low-dose droperidol and found no increase in serious cardiac events compared to placebo.

Extrapyramidal symptoms are more common in young women, children, and patients receiving concurrent dopamine antagonists (such as metoclopramide). These symptoms are usually reversible and respond to anticholinergic therapy. The risk of tardive dyskinesia, which is associated with long-term antipsychotic use, is essentially absent with the single-dose or short-course use typical of droperidol in clinical practice.

How Should You Store Droperidol Sintetica?

Droperidol Sintetica is a hospital-only medication and is stored and managed by clinical pharmacy departments. However, proper storage conditions are essential to maintain the chemical stability and therapeutic efficacy of the product:

• Temperature: Store below 25°C (77°F). Do not refrigerate or freeze.
• Light protection: Store in the original outer carton to protect from light. Droperidol is sensitive to photodegradation.
• After opening: For single-use ampoules, any unused portion should be discarded immediately after use. The solution does not contain preservatives.
• Shelf life: Do not use after the expiry date printed on the carton and ampoule label. The expiry date refers to the last day of that month.
• Visual inspection: Before use, the solution should be inspected visually. It should be a clear, colourless to pale yellow solution. Do not use if the solution is discoloured, cloudy, or contains particulate matter.

Do not dispose of medicines via wastewater or household waste. Follow local regulations and institutional policies for the disposal of unused pharmaceutical products. This helps protect the environment.

What Does Droperidol Sintetica Contain?

Droperidol Sintetica is a sterile, preservative-free solution for injection. Understanding its complete composition is important for healthcare professionals, particularly when assessing compatibility with other intravenous medications and when caring for patients with known sensitivities to specific excipients.

Active Ingredient

• Droperidol – 0.5 mg per ml. Droperidol (chemical name: 1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydro-4-pyridinyl}-1,3-dihydro-2H-benzimidazol-2-one) is a butyrophenone derivative with a molecular weight of 379.43 g/mol. It appears as a white to slightly yellowish crystalline powder.

Excipients

• Tartaric acid – Used as a pH buffering agent to maintain the solution within its optimal pH range (3.0–3.8)
• Sodium hydroxide – Used for pH adjustment
• Water for injections – The solvent vehicle, meeting pharmacopoeial standards for parenteral preparations

The solution is presented in clear glass ampoules. Droperidol Sintetica does not contain preservatives, antimicrobial agents, lactose, gluten, or any components derived from animal sources. Each ampoule is intended for single use only. From a compatibility perspective, droperidol solution is physically compatible with most commonly used intravenous fluids including 0.9% sodium chloride and 5% glucose. However, it should not be mixed with other medications in the same syringe unless compatibility data are available.